Hironobu Maezaki

This inventor holds 15 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 7 EPO patents, primarily in Heterocyclic Compounds. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2009-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hironobu Maezaki. Retrieved from https://idiyas.com/inventor/hironobu-maezaki

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 2)

% Patents Active = 93.3

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 7 (Patent Applications = 13)

Average Co-Inventor Count = 6.5

ph-index = 2

Forward Citations = 26(Granted Patents)

Location History:

Toyonaka, JP (2009)
Osaka, JP (2013 - 2023)
Kanagawa, JP (2017 - 2024)

Company Filing History:

15 out of 1,229

Takeda Pharmaceutical Company Limited

patents

Years Active: 2009-2025

Loading Chart...

Areas of Expertise:

CDK12 Inhibitors

Peptidase Inhibitors

Nitrogen-Containing Compounds

Bicyclic Compound

Monocyclic Compound

Tricyclic Compound

Fused Compounds

Condensed-Cyclic Compound

Heterocyclic Chemistry

Chemical Inhibitors

Pharmaceutical Chemistry

Drug Development

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12435063 - Nitrogen containing heterocycles as CDK12 inhibitors (2025-10-07),

2. 12378256 - Heterocyclic compound (2025-08-05),

3. 12162864 - Condensed-cyclic compound (2024-12-10),

4. 12084436 - Heterocyclic compound (2024-09-10),

5. 12012419 - Heterocyclic compound (2024-06-18),

6. RE49686 - Nitrogen-containing heterocyclic compound and use of same (2023-10-10),

7. 11584737 - Heterocyclic compound (2023-02-21),

8. 11236099 - Heterocyclic compound (2022-02-01),

9. RE48334 - Nitrogen-containing heterocyclic compound and use of same (2020-11-30),

10. 10435399 - HDAC6 inhibitory heterocyclic compound (2019-10-08),

11. 10301292 - Bicyclic compound (2019-05-28),

12. 10252997 - Monocyclic compound (2019-04-09),

13. 9556200 - Tricyclic compound (2017-01-31),

14. 8592454 - Nitrogen-containing heterocyclic compound and use of same (2013-11-26),

15. 7547710 - Fused heterocyclic compounds as peptidase inhibitors (2009-06-16),

Title: The Innovative Mind of Hironobu Maezaki

Introduction: Hironobu Maezaki, based in Kanagawa, Japan, has made significant contributions to the field of pharmaceuticals through his inventive spirit. With a portfolio of 13 patents, Maezaki showcases his dedication to developing novel compounds aimed at addressing various health issues.

Latest Patents: Among his latest innovations, Maezaki has created a condensed-cyclic compound designed for the prophylaxis or treatment of constipation. This compound, represented by a specific formula in his patent, offers potential therapeutic benefits. Additionally, he has developed a heterocyclic compound with HDAC inhibitory action, which holds promise for treating central nervous system diseases, including neurodegenerative disorders. This invention is also detailed by a specific formulation outlined in his patent documentation.

Career Highlights: Hironobu Maezaki is currently associated with Takeda Pharmaceutical Company Limited, a prominent player in the global pharmaceutical industry. His work at Takeda reflects his commitment to advancing medical science and improving patient outcomes through innovative solutions.

Collaborations: Maezaki collaborates with talented colleagues, including Ayumu Sato and Yasutomi Asano. Together, they contribute to the creation of impactful drugs and therapies that tackle pressing health challenges.

Conclusion: Hironobu Maezaki's ongoing innovations and strong pharmaceutical background highlight his role as a vital contributor to the industry. His patents not only reflect his ingenuity but also his dedication to improving healthcare and enhancing the quality of life for many individuals.

Profile summary based on public USPTO records.